ReviewNPJ breast cancer2026

Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer.

Serena Di Cosimo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.